AU Patent

AU2015358615B2 — Anti-CD38 antibodies for treatment of acute myeloid leukemia

Assigned to Janssen Biotech Inc · Expires 2021-08-05 · 5y expired

What this patent protects

The present invention relates to methods of treatment of acute myeloid leukemia with anti- CD38 antibodies.

USPTO Abstract

The present invention relates to methods of treatment of acute myeloid leukemia with anti- CD38 antibodies.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2015358615B2
Jurisdiction: AU
Classification: —
Expires: 2021-08-05
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.